# PROMETHERA Biosciences S.A./N.V.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/promethera-biosciences-s-a-n-v

- Industry: Biotechnology
- Headquarters: Belgium
- Website: www.promethera.com
- Total disclosed funding: $69M
- Latest round: Series D (Dec 16, 2019)
- Investors on record: 26

## About

Based in Mont-Saint-Guibert, Belgium, and founded in 2009, Prothera Biosciences S.A/N.V. operates as a biosciences firm that offers cell therapy research. The company was founded by Etienne Sokal. In December 2019, PROMETHERA Biosciences S.A./N.V. raised EUR 7.5 million in series D funding co-led by Sony Ventures, Fenox Venture Capital, Medipal Holdings Co., Ltd, and Six Snow.

The firm develops stem cell treatments for patients and helps them by restoring liver health. It helps patients in need of liver transplantation by providing a potential alternative to transplantation or helps them by gaining more time till transplant by stabilizing disease progression. It offers cell-therapy treatment, HepaStem™ which provides anti-fibrotic, anti-inflammatory, and immunomodulatory benefits.

## Funding rounds

- Series D, Dec 16, 2019, $7.8M — Pegasus Tech Ventures, Medipal Holdings Co., Ltd, Sony Innovation Fund, Six Snow
- Series D, May 16, 2019, $13M — Mitsui Global Investment, Korea Investment Partners, Mirae Asset Capital, Medipal Holdings Co., Ltd, Shinsei Capital Partners, Six Snow, Ci:z Investment LLP
- Series C, Nov 14, 2016, $11M — Mitsui Global Investment, Société Régionale d'Investissement de Wallonie, Vesalius Biocapital, Boehringer Ingelheim Venture, Mitsubishi UFJ Capital, Fund+, Cell Innovation Partners, SMS Investments, LifeLiver Co., Ltd.
- Series C, Dec 9, 2014, $7.5M — Mitsui Global Investment, Vives, Société Régionale d'Investissement de Wallonie, Shire, Vesalius Biocapital, Boehringer Ingelheim Venture, SFPI-FPIM, ATMI
- Series B, Apr 16, 2012, $22M — Mitsui Global Investment, Shire, Boehringer Ingelheim Venture, Sambrinvest, ATMI
- Series A, Nov 12, 2009, $7.9M — Vives, LRM, Société Régionale d'Investissement de Wallonie, Vesalius Biocapital, Life Sciences Research Partners, Invest.BW, Capital & Croissance

## Investors

- Vives (https://capitalatlas.ai/funds/vives) — Series A, Series C
- LRM (https://capitalatlas.ai/funds/lrm) — Series A
- Société Régionale d'Investissement de Wallonie — Series A, Series C
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series A, Series C
- Life Sciences Research Partners — Series A
- Invest.BW (https://capitalatlas.ai/funds/invest-bw) — Series A
- Capital & Croissance — Series A
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series B, Series C, Series D
- Shire — Series B, Series C
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series B, Series C
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Series B
- ATMI — Series B, Series C
- SFPI-FPIM — Series C
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series C
- Fund+ (https://capitalatlas.ai/funds/fund) — Series C
- Cell Innovation Partners (https://capitalatlas.ai/funds/cell-innovation-partners) — Series C
- SMS Investments — Series C
- LifeLiver Co., Ltd. — Series C
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series D
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series D
- Medipal Holdings Co., Ltd — Series D
- Shinsei Capital Partners (https://capitalatlas.ai/funds/shinsei-capital-partners) — Series D
- Six Snow — Series D
- Ci:z Investment LLP — Series D
- Pegasus Tech Ventures (https://capitalatlas.ai/funds/pegasus-tech-ventures) — Series D
- Sony Innovation Fund (https://capitalatlas.ai/funds/sony-innovation-fund) — Series D